Jin Sup Park1,2, Kwang Soo Cha3,4, Hye Won Lee1, Jun-Hyok Oh1, Jung Hyun Choi1, Han Cheol Lee1, Taek Jong Hong1, Myung Ho Jeong5, Shung Chull Chae6, Young Jo Kim7. 1. Department of Cardiology, Pusan National University Hospital, Busan, South Korea. 2. Medical Research Institute, Pusan National University Hospital, Busan, South Korea. 3. Department of Cardiology, Pusan National University Hospital, Busan, South Korea. chakws1@hanmail.net. 4. Medical Research Institute, Pusan National University Hospital, Busan, South Korea. chakws1@hanmail.net. 5. Department of Cardiology, Chonnam National University Hospital, Gwangju, South Korea. 6. Department of Cardiology, Kyungpook National University Hospital, Daegu, South Korea. 7. Department of Cardiology, Yeungnam University Hospital, Daegu, South Korea.
Abstract
BACKGROUND: It is unclear whether high-density lipoprotein cholesterol (HDL-C) level predicts cardiovascular events and has a protective effect in patients with acute myocardial infarction (AMI) undergo- ing percutaneous coronary intervention (PCI) and statin treatment. METHODS: A total of 15,290 AMI patients receiving statins were selected from the Korean Myocardial Infarction Registry. Baseline HDL-C level was used to identify patients with low (group A), normal (group B), and high (group C) HDL-C levels according to the Adult Treatment Panel III criteria. Clinical outcomes were compared in propensity-adjusted and matched cohorts. The primary endpoint was a composite of cardiovascular death and recurrent myocardial infarction. RESULTS: At the median follow-up of 11.5 months, the primary endpoint occurred in 2.7% (112/4098), 1.4% (54/3910), and 1.2% (8/661) of patients in groups A, B, and C, respectively. In the propensity- -adjusted cohort, low HDL-C level increased the risk of primary endpoint (hazard ratio [HR] 1.755, 95% confidence interval [CI] 1.274-2.417, p = 0.001), whereas high HDL-C level did not reduce this risk (HR 0.562, 95% CI 0.275-1.146, p = 0.113). In the propensity-matched cohort, low HDL-C level increased the risk of primary endpoint (HR 1.716, 95% CI 1.210-2.434, p = 0.002), whereas high HDL-C level reduced this risk (HR 0.449, 95% CI 0.214-0.946, p = 0.035). CONCLUSIONS: In AMI patients treated with PCI and statins, low HDL-C level increases the risk of cardiovascular death and recurrent myocardial infarction, whereas high HDL-C level likely reduces the risk of cardiovascular events, especially for ST-elevation myocardial infarction.
BACKGROUND: It is unclear whether high-density lipoprotein cholesterol (HDL-C) level predicts cardiovascular events and has a protective effect in patients with acute myocardial infarction (AMI) undergo- ing percutaneous coronary intervention (PCI) and statin treatment. METHODS: A total of 15,290 AMI patients receiving statins were selected from the Korean Myocardial Infarction Registry. Baseline HDL-C level was used to identify patients with low (group A), normal (group B), and high (group C) HDL-C levels according to the Adult Treatment Panel III criteria. Clinical outcomes were compared in propensity-adjusted and matched cohorts. The primary endpoint was a composite of cardiovascular death and recurrent myocardial infarction. RESULTS: At the median follow-up of 11.5 months, the primary endpoint occurred in 2.7% (112/4098), 1.4% (54/3910), and 1.2% (8/661) of patients in groups A, B, and C, respectively. In the propensity- -adjusted cohort, low HDL-C level increased the risk of primary endpoint (hazard ratio [HR] 1.755, 95% confidence interval [CI] 1.274-2.417, p = 0.001), whereas high HDL-C level did not reduce this risk (HR 0.562, 95% CI 0.275-1.146, p = 0.113). In the propensity-matched cohort, low HDL-C level increased the risk of primary endpoint (HR 1.716, 95% CI 1.210-2.434, p = 0.002), whereas high HDL-C level reduced this risk (HR 0.449, 95% CI 0.214-0.946, p = 0.035). CONCLUSIONS: In AMI patients treated with PCI and statins, low HDL-C level increases the risk of cardiovascular death and recurrent myocardial infarction, whereas high HDL-C level likely reduces the risk of cardiovascular events, especially for ST-elevation myocardial infarction.
Authors: Peter P Toth; Marcin Barylski; Dragana Nikolic; Manfredi Rizzo; Giuseppe Montalto; Maciej Banach Journal: Best Pract Res Clin Endocrinol Metab Date: 2013-11-15 Impact factor: 4.690
Authors: Subroto Acharjee; Matthew T Roe; Ezra A Amsterdam; DaJuanicia N Holmes; William E Boden Journal: Am J Cardiol Date: 2013-07-25 Impact factor: 2.778
Authors: Mi Seon Ji; Myung Ho Jeong; Young Keun Ahn; Young Jo Kim; Shung Chull Chae; Taek Jong Hong; In Whan Seong; Jei Keon Chae; Chong Jin Kim; Myeong Chan Cho; Seung-Woon Rha; Jang Ho Bae; Ki Bae Seung; Seung Jung Park Journal: J Cardiol Date: 2014-09-18 Impact factor: 3.159
Authors: Yun Ah Jeong; Myung Ho Jeong; Hae Chang Jeong; Youngkeun Ahn; Young Jo Kim; Chong Jin Kim; Myeong Chan Cho Journal: Korean Circ J Date: 2015-01-26 Impact factor: 3.243
Authors: Doo Sun Sim; Myung Ho Jeong; Kyung Hoon Cho; Youngkeun Ahn; Young Jo Kim; Shung Chull Chae; Taek Jong Hong; In Whan Seong; Jei Keon Chae; Chong Jin Kim; Myeong Chan Cho; Seung-Woon Rha; Jang Ho Bae; Ki Bae Seung; Seung Jung Park Journal: Korean Circ J Date: 2013-02-28 Impact factor: 3.243
Authors: Piotr Pęczek; Mateusz Leśniewski; Tomasz Mazurek; Lukasz Szarpak; Krzysztof J Filipiak; Aleksandra Gąsecka Journal: Life (Basel) Date: 2021-05-23
Authors: Diego Estrada-Luna; María Araceli Ortiz-Rodriguez; Lizett Medina-Briseño; Elizabeth Carreón-Torres; Jeannett Alejandra Izquierdo-Vega; Ashutosh Sharma; Juan Carlos Cancino-Díaz; Oscar Pérez-Méndez; Helen Belefant-Miller; Gabriel Betanzos-Cabrera Journal: Molecules Date: 2018-10-23 Impact factor: 4.411